What the PCAC Vote Changes for Your Peptide Store: The Correct Answer

By Peptide Ecommerce · August 10, 2026

If you read a headline in July 2026 saying something like "FDA committee supports peptides including BPC-157 and TB-500," you may have wondered what that means for your research-use-only storefront. The short answer: nothing changes for RUO operators. The PCAC vote was advisory and non-binding (FDA). Nothing was added to the 503A bulks list as a result. No peptide became legal to compound, prescribe, or sell under a different regulatory framework than it was under before the vote.

Key Facts

PCAC supplies independent expert recommendations to FDA (FDA).
FDA evaluates bulk substances using physical and chemical characterization, safety issues, evidence of effectiveness and historical compounding use (Office of the Federal Register / eCFR).
FDA uses product labeling and website claims as evidence of intended use (FDA).
Section 503A permits compounding by licensed pharmacists and licensed physicians (FDA).
The FTC requires truthful advertising supported by evidence.

TL;DR

Businesses using Stripe's services must comply with its published business restrictions.
FDA issued an August 2026 warning letter to Peak Performance Peptides following a July review of its website (FDA).
PCAC's vote was an advisory recommendation to FDA on compounding.

What the PCAC Is

The Pharmacy Compounding Advisory Committee (PCAC) is an FDA advisory committee that evaluates substances for their potential inclusion on the 503A bulks list (FDA). The 503A bulks list is a list of substances that licensed pharmacists and licensed physicians compounding under section 503A of the Federal Food, Drug, and Cosmetic Act may use as bulk drug substances in compounded preparations.

The PCAC is an FDA advisory body. It provides advisory recommendations to the FDA. FDA considers that advice in its regulatory process and changes the 503A bulks list through notice and comment rulemaking (FDA / Federal Register).

PCAC advises FDA on drug compounding. The 503A bulks list applies to qualifying compounding by licensed pharmacists and licensed physicians. For your storefront, FDA evaluates intended use from labeling, marketing and distribution, and applies the drug requirements that follow from that evidence (FDA).

What the July 2026 Vote Was

On July 23 and 24, 2026, the PCAC met and conducted advisory reviews of seven substances: BPC-157 (free base and acetate), KPV, TB-500, MOTS-c, Emideltide (also called DSIP), Semax, and Epitalon (FDA). FDA evaluates physical and chemical characterization, safety issues, evidence of effectiveness and historical compounding use. Its review also considers the nominated uses and available alternatives.

Six of the seven substances received favorable advisory votes. BPC-157 and TB-500 each passed by an 8-to-6 vote with one abstention. KPV, MOTS-c, Semax, and Epitalon also received favorable votes. Emideltide received an unfavorable vote (6 in favor, 7 opposed, one abstention).

FDA's scientific staff recommended against adding BPC-157 and TB-500 to the 503A bulks list (FDA: BPC-157 briefing, FDA: TB-500 briefing). The committee voted favorably for both substances despite that staff recommendation. The committee's favorable votes are advisory to the FDA. FDA considers the scientific review and advisory recommendations when deciding how to proceed with rulemaking.

A "favorable" vote from the committee means the committee found the substance suitable under the evaluation criteria. It is a recommendation. FDA makes the regulatory decisions, with additions to the 503A bulks list established through notice and comment rulemaking (FDA / Federal Register).

What the Vote Means for 503A Compounding and Your Store

The PCAC vote was an advisory recommendation to FDA. FDA makes the regulatory decision on any change to the 503A bulks list.

A favorable PCAC vote moves a substance closer to potential 503A eligibility for licensed pharmacists and licensed physicians.

Section 503A compounding requirements apply to licensed pharmacists and licensed physicians. A favorable PCAC vote supplies advice for FDA's evaluation of the 503A bulks list. Your storefront's obligations continue to depend on its products, intended uses and activities, with FDA evaluating labeling, marketing and distribution (FDA).

What the Vote Leaves Unchanged for RUO Operators

To be explicit:

The vote does not add BPC-157, TB-500, or any other reviewed peptide to the 503A bulks list. The list did not change as a result of the vote.

Section 503A applies to qualifying compounding by licensed pharmacists in state licensed pharmacies or federal facilities and by licensed physicians (FDA). These activities remain subject to the applicable statutory conditions, while PCAC's vote serves as advice to FDA.

FDA evaluates a product's intended use from labeling, marketing and distribution (Cornell Legal Information Institute). The resulting legal requirements continue to govern your sales while FDA considers PCAC's recommendations on compounding substances.

Your product's labeling obligations follow from its intended use and the applicable legal requirements. FDA considers labeling alongside marketing and distribution when evaluating intended use (Cornell Legal Information Institute).

Marketing language remains governed by the same legal requirements as before the vote. If you were not allowed to make a particular claim about a product before the vote, you are not allowed to make it after the vote.

What It Means for RUO Operators: Nothing Changes Legally

Your storefront's legal obligations remain tied to its products and intended uses. FDA evaluates labeling, marketing and distribution, including communications that indicate human use. Payment providers apply their own terms; for example, businesses using Stripe's services must comply with its current business restrictions (Stripe).

Do not change your labeling in response to the PCAC vote. Do not change your marketing language. Do not imply in any customer communication or product description that a favorable committee vote signals regulatory approval, legality, or compoundability of any product you sell. That implication would be false and would constitute a compliance violation.

What to Watch For

FDA rulemaking is the event that changes the codified 503A bulks list. A proposed amendment sets out the agency's proposal and public comment procedures. FDA considers the comments before deciding how to proceed, and an adopted amendment changes the list according to the final rule's terms and effective date (FDA / Federal Register).

The rulemaking trajectory for BPC-157 and TB-500 is particularly uncertain because FDA's own scientific staff recommended against inclusion, a recommendation the committee's favorable vote did not follow. When the committee and the FDA scientific staff disagree, the agency's subsequent rulemaking decision can go in either direction. FDA is not bound by the committee's favorable vote and may proceed with rulemaking in either direction. Operators should monitor the Federal Register for any proposed rule and maintain current compliance practices in the meantime.

The FDA Center for Drug Evaluation and Research (CDER) maintains the current, confirmed 503A bulks list.

Your storefront's compliance obligations depend on its products, labeling, intended uses and business activities. FDA evaluates intended use from labeling, marketing and distribution. Labeling and processor compliance documentation support that review, and payment providers publish their own business terms; Stripe's users must remain compliant with its restrictions.

Frequently Asked Questions

Who oversees a state licensed compounding pharmacy?

State boards of pharmacy generally have primary responsibility for daily oversight of state licensed pharmacies operating outside the outsourcing facility registration system. FDA also conducts surveillance and inspections of those pharmacies.

Where do payment provider obligations appear?

Payment providers set their own business restrictions in their terms of service. For example, businesses using Stripe's services must remain compliant with its published rules and restrictions.

What did FDA examine in a peptide storefront review after the meeting?

FDA's August 2026 letter to Peak Performance Peptides describes a July review of its website. FDA cited product descriptions and the way products were offered together as evidence of intended use.

Sources

Considering outside help? Questions to ask before choosing a peptide business coach